Suppression of the proliferation and invasion of breast cancer cells by ST7L occurs through inhibition of activation of Wnt/GSK-3 β/β-catenin signaling.

This article is protected by copyright. All rights reserved. PMID: 31429477 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Pharmacology and Physiology - Category: Drugs & Pharmacology Authors: Tags: Clin Exp Pharmacol Physiol Source Type: research

Related Links:

Publication date: Available online 17 September 2019Source: Pathology - Research and PracticeAuthor(s): Banita Thakur, Yashwant Kumar, Alka BhatiaAbstractBreast cancer is one of the major causes of cancer related deaths in women worldwide. A major factor responsible for treatment failure in breast cancer is the development of resistance to commonly used chemotherapeutic drugs leading to disease relapse. Several studies have shown dysregulation of molecular machinery of apoptosis, the major programmed cell death pathway in breast malignancies. Thus, there is an unmet need to search for an alternative cell death pathway whic...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Publication date: Available online 17 September 2019Source: SteroidsAuthor(s): Anjali Verma, Nofrat Schwartz, D. Joshua Cohen, Barbara D. Boyan, Zvi SchwartzAbstractLaryngeal squamous cell carcinoma (LSCC) has been shown to respond to 17β-estradiol. However, the presence and characterization of estrogen receptors (ER) and other sex hormone receptors in LSCC are still being determined. Sex hormone receptors and the way sex hormones impact LSCC tumors are important for understanding which patients would benefit from hormone therapies, such as anti-estrogen therapies. This information also has prognostic value, as there ...
Source: Steroids - Category: Drugs & Pharmacology Source Type: research
ConclusionsHigh CEL expression may be an independent prognostic factor for the poor survival of breast cancer.
Source: Cancer Genetics - Category: Cancer & Oncology Source Type: research
I defeated breast cancer, but am still battling the cognitive changes left behind after two years of intense treatment. Eight surgeries, six chemotherapy treatments, 25 radiation appointments, and two bouts of infection changed my body forever. I’m OK with that, because everything was done to keep me alive. All signs point to these efforts succeeding. But one remnant of the battle didn’t get left behind with the wigs and empty medicine bottles: chemo brain. “Chemo brain” is a common term used for the attention and memory issues often caused by cancer treatment—although these issues are thought...
Source: American Speech-Language-Hearing Association (ASHA) Press Releases - Category: Speech-Language Pathology Authors: Tags: Health Care Private Practice Slider Speech-Language Pathology Cognitive Rehabilitation Source Type: blogs
This study assesses the clinical effect of SFI combined with chemotherapy for breast cancer patients. Materials and methods: Both English and Chinese databases were searched covering the time period of 1999- 2018 for relevant studies comparing the effect of SFI plus chemotherapy treatment with chemotherapy alone in patients with breast cancer. Target outcomes concerning treatment effect, performance status, immune system and toxic effects were extracted and combined using Stata version 15.0 software. Quality assessment was performed using the Jadad scale. Results: Forty-nine trials were included based on certain selection ...
Source: Pharmaceutical Biology - Category: Drugs & Pharmacology Tags: Pharm Biol Source Type: research
Chemoprevention for breast cancer should be discussed at well-woman care visits, but this is a'big ask'of primary care physicians, says one who specializes in this area.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
The evening will feature a wellness fair where experts will share the latest information on wellness, cancer prevention, screening and breast health.
Source: SUNY Upstate Medical - Category: Universities & Medical Training Source Type: news
Condition:   Breast Cancer Intervention:   Genetic: XIST gene deletion Sponsor:   Assiut University Not yet recruiting
Source: - Category: Research Source Type: clinical trials
This 61-year-old woman presented with new primary triple negative breast cancer (TNBC) in the lateral breast 10 years after completing radiation for ductal carcinoma in situ (DCIS) in the same breast.1 Despite neoadjuvant chemotherapy and mastectomy with only residual DCIS and negative nodes, patient developed a TNBC re-recurrence only 9 months later. She was treated with chemotherapy, and there remains positive residual localized disease by positron emission tomography (PET). At this point we recommend the following.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research
Although we report an increased rate of grade (G) 2 or greater radiation dermatitis (RD), predominantly driven by G2 toxicity, we do not describe a doubling in the overall rate of RD seen in patients with breast cancer undergoing adjuvant proton pencil-beam scanning (PBT). We advise counseling patients of the potential for increased dermatologic toxicity, though this should not affect modality selection, considering a very low number of patients experienced G3 to G4 RD.1Although it is notable that this increased toxicity occurs in the absence of bolus, we do not conclude that PBT should be used in lieu of photon radiation ...
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Comment Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Drugs & Pharmacology | Physiology | Study